Rahmet Güner1, Siran Keske2, Imran Hasanoğlu3, Mehmet Taşyaran1. 1. Department of Infectious Diseases and Clinical Microbiology, Yıldırım Beyazıt University Faculty of Medicine, Ankara, Turkey. 2. Department of Infectious Diseases and Clinical Microbiology, Polatlı Duatepe State Hospital, Ankara, Turkey. 3. Department of Infectious Diseases and Clinical Microbiology, Atatürk Education and Research Hospital, Ankara, Turkey.
Abstract
BACKGROUND: Pityriasis rosea is an acute inflamatory skin disease that the etiology is unknown but some viral agents like human herpes virus-6 and 7 and drugs are suspected. CASE REPORT: A-58-year-old man with chronic hepatitis C was being followed up in our hospital. Pegylated interferon (PEG-IFN) alfa-2b (100 μg per week) and ribavirin (1000 mg/day) was started. In the third month of this treatment, the patient was diagnosed with pityriasis rosea (PR), which was confirmed by skin biopsy. PEG-IFN alfa-2b treatment for chronic hepatitis C was maintained and no therapy was given for PR. The lesions spontaneously improved within 5 weeks. CONCLUSION: Interferon and ribavirin have several cutaneous side effects. Our case is the first case of PR, emerged in a patient with chronic hepatitis C while receiving PEG-IFN alfa 2b and ribavirin.
BACKGROUND:Pityriasis rosea is an acute inflamatory skin disease that the etiology is unknown but some viral agents like human herpes virus-6 and 7 and drugs are suspected. CASE REPORT: A-58-year-old man with chronic hepatitis C was being followed up in our hospital. Pegylated interferon (PEG-IFN) alfa-2b (100 μg per week) and ribavirin (1000 mg/day) was started. In the third month of this treatment, the patient was diagnosed with pityriasis rosea (PR), which was confirmed by skin biopsy. PEG-IFN alfa-2b treatment for chronic hepatitis C was maintained and no therapy was given for PR. The lesions spontaneously improved within 5 weeks. CONCLUSION: Interferon and ribavirin have several cutaneous side effects. Our case is the first case of PR, emerged in a patient with chronic hepatitis C while receiving PEG-IFN alfa 2b and ribavirin.
Authors: Sang Hee Lim; Sang Min Kim; Byung Ho Oh; Jong Hyun Ko; Yang Won Lee; Yong Beom Choe; Kyu Joong Ahn Journal: Ann Dermatol Date: 2009-08-31 Impact factor: 1.444
Authors: B Canpolat Kirac; E Adisen; G Bozdayi; A Yucel; I Fidan; N Aksakal; M A Gurer Journal: J Eur Acad Dermatol Venereol Date: 2008-08-18 Impact factor: 6.166